Oxford Biomedica plc (LON:OXB)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 726.61M |
| Revenue (ttm) | 168.74M |
| Net Income (ttm) | -30.13M |
| Shares Out | 120.90M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 222,780 |
| Average Volume | 243,317 |
| Open | 581.00 |
| Previous Close | 612.00 |
| Day's Range | 581.00 - 616.00 |
| 52-Week Range | 270.00 - 962.00 |
| Beta | 1.10 |
| RSI | 46.45 |
| Earnings Date | Jun 23, 2026 |
About Oxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary ‘plug and play’ dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical an... [Read more]
Financial Performance
In 2025, Oxford Biomedica's revenue was 168.74 million, an increase of 31.01% compared to the previous year's 128.80 million. Losses were -30.13 million, -30.24% less than in 2024.
Financial StatementsNews
Oxford BioMedica PLC (OXBDF) Full Year 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Oxford BioMedica PLC (OXBDF) Full Year 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Full Year 2025 Oxford Biomedica PLC Earnings Call Transcript
Full Year 2025 Oxford Biomedica PLC Earnings Call Transcript
Oxford Biomedica (OXBDF) Reports Strong Revenue Growth for FY
Oxford Biomedica (OXBDF) Reports Strong Revenue Growth for FY
Oxford Biomedica Earnings Call Transcript: H2 2025
Revenue grew 33% year-over-year to GBP 170.9 million, with first full year of EBITDA profitability and strong cash position. U.S. expansion, a robust order backlog, and multi-vector capabilities support above-market growth targets for 2026 and beyond.
EQT backs out of takeover bid for UK's Oxford Biomedica
Private equity group EQT said on Wednesday it had decided not to proceed with a takeover offer for Oxford Biomedica , sending the British cell and gene therapy manufacturer's shares down nearly 10%.
UK's Oxford Biomedica confirms unsolicited bid from funds managed by EQT
British cell and gene therapy manufacturer Oxford Biomedica confirmed on Wednesday that it has received an unsolicited cash offer from funds managed by EQT for all of its shares.
Oxford Biomedica Transcript: Jefferies London Healthcare Conference 2025
A focused CDMO in Cell and Gene Therapy reported strong order growth, expanded U.S. operations with a new Durham facility, and enhanced financial flexibility. Innovation and operational improvements support ambitious revenue and profitability targets for 2025–2028.
Oxford Biomedica Transcript: Stifel 2025 Healthcare Conference
A global CDMO specializing in viral vectors for cell and gene therapy is expanding its US and EU footprint, achieving strong revenue growth and targeting 25–30% annual growth through 2028. Recent investments and acquisitions support capacity, while innovation and expertise drive competitive advantage.
Oxford Biomedica Earnings Call Transcript: H1 2025
H1 2025 saw 44% revenue growth and a 166% rise in contracted orders, with profitability improving and a strengthened balance sheet. Strategic investments and a robust pipeline support guidance for sustained double-digit growth and margin expansion through 2028.
UK's Oxford Biomedica maintains annual outlook
Britain's Oxford Biomedica on Monday maintained its annual forecasts for revenue and profit after it said first-half sales are expected to jump around 40% as orders remain strong for the cell and gene...
OXB completes acquisition of remaining stake in US subsidiary
OXB completes acquisition of remaining stake in US subsidiary Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, U...
Oxford Biomedica Earnings Call Transcript: H2 2024
Organic revenue grew 81% and total revenue rose 44% to GBP 128.8 million in 2024, with strong commercial momentum and a narrowed EBITDA loss. 2025 guidance targets GBP 160–170 million in revenue and a return to profitability, supported by a robust pipeline and high order coverage.
Oxford Biomedica Earnings Call Transcript: H1 2024
Strong H1 2024 organic revenue growth of 38% and a maturing pipeline drove improved financials, with reduced losses and a robust order book. Guidance for 2024–2026 remains unchanged, supported by high suite utilization and strong commercial momentum.
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and innov...
Oxford Biomedica announces CFO transition
Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OX...
Oxford Biomedica Earnings Call Transcript: H2 2023
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica's position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites...
Oxford Biomedica is hosting a free webinar to share clients' success stories in viral vector manufacturing
Oxford Biomedica is hosting a free webinar to share clients' success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and innova...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
The non-exclusive, multi-year license and supply agreement enables use of LentiVector ® with any Kyverna product Agreement supports Kyverna's scalability and reliability of CAR T cell manufacturing go...
Oxford Biomedica Earnings Call Transcript: H1 2023
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domest...
Oxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe
Oxford Biomedica's shares jumped as much as 16% on Wednesday after the British cell and gene therapy company said it would break even earlier than expected and that it was in exclusive talks to buy vi...